**LICENSE      AGREEMENT**

----

**Article      1.0**
**Definitions**

| 1.1.   | “Affiliate”                means with respect to a party, any other business entity that directly                or                indirectly controls, is controlled by, or is under common control                with,                such party. A business entity or party shall be regarded as in control                of                another business entity if it owns, or directly or indirectly controls,                at                least fifty percent (50%) of the voting stock or other ownership                interest                of the other business entity, or if it directly or indirectly possesses                the power to direct or cause the direction of the management and                policies                of the other business entity by any means whatsoever. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2.   | “Control”                or “Controlled”                means, with respect to any intellectual property right, possession                of the                ability to grant the other party access, a license or sublicense                (as                applicable) as provided for herein without violating the terms of                any                agreement or other arrangement with any third party existing at the                time                such party would be first required hereunder to grant the other party                such                access, license or sublicense. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3.   | “DOV                Patents”                means (i) the patents and patent applications listed in Exhibit B,                all patents issuing on such patent applications, plus all other Patents                Rights that claim priority to, in whole or in part, directly or                indirectly, one or more of any such patents or patent applications,                plus                (ii) all other Patent Rights Controlled by DOV or any of its Affiliates,                as of the Effective Date or thereafter during the term of this Agreement,                that are necessary for the manufacture, use sale, offer for sale,                importation, research, development or commercialization or other                exploitation of any Product or Marketed Product solely for use in                the                Retained Rights Field,*provided, however*,                that for this clause (ii) such other Patent Rights shall not                include (1) any Patent Right directed to or claiming any                manufacturing technology that is not required for the manufacture                of such                Product or Marketed Product (*e.g.*,                if the Product or Marketed Product is amenable to being manufactured                by a                method that is not covered by the applicable other Patent Right,                such                other Patent Right would not be considered to be a DOV Patent for                purposes                of this Agreement) or (2) any Patent Right directed to or claiming                any pharmaceutical formulation                technology. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.4.   | “Field”                means the treatment of any diseases, disorders and conditions in                humans,                other than any disease, disorder or condition within the Retained                Rights                Field. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.5.   | “Marketed                Product”                means a pharmaceutical preparation in finished form containing Product                suitable for human administration, whether alone or in combination                with                other active ingredients. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.6.   | “Net                Sales”                shall mean the gross amount invoiced for the Marketed Product sold,                distributed or otherwise disposed of by DOV and/or its Affiliates                or its                sublicensees (including any further sublicensees), in an arm’s length                transaction to an end user (“Gross                Sales”),                less: |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | transportation                charges or allowances, if any, included in such                price; |
|-----------------|-----------------------------------------------------------------------------------------------------|

| (ii)   | trade,                quantity or cash discounts, service allowances and broker’s or agent’s                commissions, but not salaries, commissions, bonuses or other incentive                pay                to in-house sales or other personnel if any, allowed or                paid; |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iii)   | credits                or allowances, if any, given or made on account of price adjustments,                returns, bad debts, off-invoice promotional discounts, rebates, and                any                all Federal, state or local government rebates whether in existence                now or                enacted at any time during the term of this Agreement (e.g., HCFA                or                Medicaid rebates), rejections, recalls or destruction requested or                made by                an appropriate government agency;                and |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (iv)   | any                tax, excise or governmental charge upon or measured by the sale,                transportation, delivery or use of the Marketed Product; |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.7.   | “Patent                Rights”                shall mean all patents and patent applications, including, without                limitation, all provisional applications, substitutions, continuations,                continuations-in-part, divisions, and renewals, all patents granted                thereon, and all patents-of-addition, reissues, reexaminations, extensions                and extended exclusivities (including, without limitation, supplementary                protection certificates and pediatric extensions) or restorations                by                existing or future extension or restoration                mechanisms. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.8.   | “Product”                means any of the compounds listed in Schedule 1,                plus any and all prodrugs, optical isomers, hydrates, solvates, salt                forms                and polymorphs of such compounds. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.9.   | “Retained                Rights Field”                means the treatment or amelioration of vasomotor symptoms caused                by or                occurring in relation to or connection with menopause or other female                hormonal fluctuations in the patient being                treated. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.10.   | “Scheduled                Payments”                means those lump sums payable at the time of the achievement of specific                developmental activities during the development period through actual                commercial introduction of a Product following regulatory                approval. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.11.   | “Territory”                means all countries of the world. |
|-------------------|--------------------------------------------------------------------------|

| 1.12.   | “Wyeth                Know-How”                means all information, patentable or otherwise, developed, applied,                or                acquired by Wyeth as of May 22, 1997 relating to the production or                development of the Product that is reasonably useful or necessary                to                develop or manufacture Product. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.13.   | “Wyeth                Patents”                means the Wyeth Primary Patents and the Wyeth Secondary                Patents. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| 1.14.   | “Wyeth                Primary Patents”                means the (i) patents and patent applications listed in Exhibit A,                (ii) all patents issuing on such patent applications, (iii) all other                Patents Rights that claim priority to, in whole or in part, directly                or                indirectly, one or more of any of the patents or patent applications                identified in (i) or (ii) above, and (iv) those other Patent Rights                Controlled by Wyeth or any of its Affiliates, as of the Effective                Date or                thereafter during the term of this Agreement, which other Patent                Rights                relate solely to and may be used solely for the manufacture or use                of the                Product or Marketed Product in the Field, *provided,                however*,                that such other Patent Rights of this clause (iv) shall not include                (a) any Patent Right directed to or claiming any manufacturing technology                that is not required for the manufacture of such Product or Marketed                Product (*e.g.,*                if                the Product or Marketed Product is amenable to being manufactured                by a                method that is not covered by the applicable other Patent Right,                such                other Patent Right would not be considered to be a Wyeth Primary                Patent                for purposes of this Agreement) or (b) any Patent Right directed                to or                claiming any pharmaceutical formulation                technology. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.15.   | “Wyeth                Secondary Patents”                means all Patent Rights (other than the Wyeth Primary Patents) Controlled                by Wyeth or any of its Affiliates, as of the Effective Date or thereafter                during the term of this Agreement, that are necessary for the manufacture,                use, sale, offer for sale, importation, research, development or                commercialization or other exploitation of any Product or Marketed                Product, *provided,                however*,                that such Patent Rights shall not include (i) any Patent Right directed                to                or claiming any manufacturing technology that is not required for                the                manufacture of such Product or Marketed Product (*e.g.*,                if the Product or Marketed Product is amenable to being manufactured                by a                method that is not covered by the applicable other Patent Right,                such                other Patent Right would not be considered to be a Wyeth Secondary                Patent                for purposes of this Agreement) or (ii) any Patent Right directed                to or                claiming any pharmaceutical formulation                technology. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.16.   | “Wyeth’s                Place of Payment”                means 500 Arcola Road, Collegeville, Pennsylvania                19426. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.17.   | As                used in this Agreement, the singular includes the plural and the                plural                includes the singular, wherever appropriate by fact or by                context. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      2.0**
**License      Grant**
**s**

| 2.1.   | As                of May 29, 1998, Wyeth hereby grants, for itself and its Affiliates,                to                DOV and its Affiliates, an exclusive (even as to Wyeth and its Affiliates)                license under Wyeth Patents and Wyeth Know-How (a) to make, have                made and                develop (subject to Article 3.4)                Product and Marketed Product in the Territory and (b) to use, sell,                offer                to sell, import and commercialize Product and Marketed Product in                the                Field in the Territory.                For the sake of clarity, DOV shall have no right under the Wyeth                Patents                or the Wyeth Know-How to make, have made, and develop any Product                and                Market Product in the Retained Rights Field, it being understood                and                agreed that Wyeth shall have the sole right to do so, subject to                Article                3.4.                For the sake of clarity, the license granted hereunder with respect                to a                Product or Marketed Product shall encompass any metabolite of such                Product                or Marketed Product resulting from human administration of such Product                or                Marketed Product, but shall not encompass the administration of any                such                metabolite as a separate pharmaceutical                product. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2.   | Subject                to Wyeth’s right of first refusal provided for in Article                4.0                and the provisions in Article                5.0,                DOV shall have the right to grant sublicenses under the license provided                for in Article 2.1.                DOV shall provide Wyeth with a true, accurate and complete copy of                each                such sublicense granted by it promptly after granting such sublicense.                In                the event that DOV grants such a sublicense to a third party, Wyeth                agrees                to negotiate in good faith and enter into with each of DOV and such                third                party a standby license under which Wyeth would grant to such third                party                (and DOV would consent to the grant to such third party of), a direct                license of the rights granted to DOV under Article 2.1                above, which direct license (i) would become effective upon the                termination (but not expiration) of this Agreement for any reason                other                than a termination by Wyeth under Article 13.4                for an uncured material breach of this Agreement which breach is                caused in                whole or in part by the actions or omissions of such third party                (ii)                would provide for such third party to promptly cure any breach of                this                Agreement remaining uncured at such time of termination, (iii) would                be on                the terms and conditions under the sublicense agreement between DOV                and                such third party, *provided,                however*,                that in no event shall such terms and conditions be any less favorable                to                Wyeth than the terms and conditions of this Agreement and (iv) would                include other terms and conditions customary for agreements of such                type.                It                is understood and agreed that in consideration for entering into                any such                direct license, Wyeth would not require such sublicensee to make                any                payments to Wyeth over and above those that would be required under                clauses (ii) and (iii) above. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.3.   | Without                limiting the scope of the license granted to DOV under Article                2.1(a),                Wyeth retains all rights under the Wyeth Patents and Wyeth Know-How                to                use, sell, offer to sell, import, develop and commercialize Product                and                Marketed Product in the Territory solely for use in the Retained                Rights                Field, in all events subject to Article 3.4.                On a country-by-country basis, Wyeth hereby agrees not to commercialize                Product or Marketed Product for use in the Field for the period during                which DOV is obligated to pay royalties hereunder on sales of Product                or                Marketed Product in such country. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.4.   | As                of the Effective Date, DOV hereby grants, for itself and its Affiliates,                to Wyeth, an exclusive license under the DOV Patents to use, develop,                sell, offer to sell, import and commercialize Product and Marketed                Product                in the Territory solely for use in the Retained Rights Field, in                all                events subject to Article 3.4                remaining in full force and effect, *provided,                however*,                that the grant of such license shall be subject to the licenses granted                to                DOV under Article 2.1,                including, without limitation, DOV’s exclusive right under the Wyeth                Patents and to use the Wyeth Know-How to make, have made and develop                Product and Marketed Product in the                Territory. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      3.0**
**Developmental      Activities**

| 3.1.   | While                this Agreement is in effect, DOV shall use reasonable efforts to                develop                and commercialize the Product, either through itself or through a                third                party commercial partner. Such activities include negotiating the                terms of                a sublicense agreement with a third                party. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2.   | DOV                may disclose unpublished Wyeth Patents and Wyeth Know-How to a third                party, bound under an obligation of confidentiality that is substantially                the same as the obligation provided for in Article                7.0                of                this Agreement, to the extent necessary to negotiate a sublicense,                and                thereafter to develop and commercialize the                Product. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3.   | On                a quarterly basis, DOV, upon Wyeth’s request, shall provide Wyeth with a                written report outlining its developmental activities during that                quarter. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4.   | In                the event that either party desires either to conduct any clinical                studies                of a Product or Marketed Product for use in the Retained Rights Field                or                to seek regulatory approval to market and sell Product or Marketed                Product                for use in the Retained Rights Field, such party shall notify the                other                and the parties shall enter into negotiations for the parties to                cooperate                in the development and commercialization of Product and Marketed                Product                on mutually agreeable terms for use in the Retained Rights Field,                *provided,                however*,                that neither party or any of their respective Affiliates or sublicensees                shall conduct any such research or development or commercialization                of any                Product or Marketed Product for use in the Retained Rights Field                without                first reaching agreement with the other party, and *provided                further*,                DOV shall not be in violation of this Article 3.4                if                a patient is treated for a disease, condition or disorder falling                within                the Retained Rights Field merely incidentally as a result of                administration of Product or Marketed Product for an indication not                falling within the Retained Rights Field (provided that for this                last                provisio neither DOV, its Affiliates or sublicensees have deliberately                taken any action, directly or indirectly, to encourage such use of                a                Product or Marketed Product). |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      4.0**
**Wyeth      Right of First Refusal**

| 4.1.   | Prior                to or simultaneously with beginning discussions with any third party                regarding a potential Partnering Agreement for Product or Marketed                Product, DOV may notify Wyeth that DOV is pursuing such discussions                and                provide Wyeth with a copy of all data and information in DOV’s possession                relating to such Product or Marketed Product. Prior to its entering                into a                Partnering Agreement with a third party with respect to Product,                DOV shall                present, in writing, to Wyeth the bona                fide                proposed terms and conditions of said Partnering Agreement (the                “Third                Party Term Sheet”).                Following receipt by Wyeth of the Third Party Term Sheet, Wyeth shall                have                thirty (30) days to notify DOV if it intends to enter into a development                agreement with DOV, the terms of which would exceed those proposed                by a                third party by ten percent (10%) relative to Scheduled Payments and                royalties, *provided,                however*,                that if DOV has not provided Wyeth with the notification, data and                information as and when contemplated under the first sentence of                this                Article 4.1,                the thirty (30) day period referenced above in this sentence shall                be                changed to sixty (60) days. So as to permit Wyeth to reach such decision,                DOV shall provide to Wyeth all relevant data and information regarding                Product available to DOV (which data was not previously provided                to Wyeth                as required under the first sentence of this Article 4.1),                simultaneously with its providing to Wyeth the terms and conditions                offered by the said third party. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.2.   | Upon                Wyeth’s providing DOV with notification of its intent to enter into an                agreement with DOV pursuant to Article 4.1,                the parties will promptly negotiate said agreement embodying Wyeth’s offer                under Article 4.1                and this Agreement shall terminate upon the effective date of said                agreement. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3.   | If                Wyeth does not notify DOV of its intention to enter into an agreement                with                DOV pursuant to Articles 4.1                and 4.2,                within the thirty (30) or sixty (60) day period provided for under                Article                4.1,                as applicable, DOV shall be free to enter into a sublicense agreement                with                the third party under the terms presented to Wyeth, or                better. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4.   | In                the event that DOV files a New Drug Application (NDA) in the USA,                or a                foreign equivalent thereof in Europe or Japan, but has not yet entered                into a license agreement with a third party for Product, DOV shall                provide                Wyeth with a copy of the NDA ( or the foreign equivalent thereof                as filed                together with its English translation) for evaluation by Wyeth. If                Wyeth                expresses an interest in marketing the Product, then the parties                shall                enter into good faith negotiations relating to the possibility of                Wyeth’s                obtaining marketing rights to the Product, provided that DOV shall                not be                required to grant by this Article 4.4                any such rights. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      5.0**
**Partnering      Agreements**

| 5.1.   | If                DOV enters into a Partnering Agreement with a third party with regard                to                Product under this Agreement, such Partnering Agreement shall provide                for                DOV to receive Scheduled Payments and royalty payments based on Net                Sales                of Marketed Product. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      6.0**
**Payments**

| 6.1.   | Within                thirty (30) days after the Effective Date of the Original License                Agreement, DOV shall pay Wyeth the fee as indicated below in this                Article                6.1                for exercising its Option rights with regard to each Product. Such                fee                shall be non-refundable and non-creditable against any other payments                due                Wyeth pursuant to this Agreement: |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| CL                216,303 |   | $ | 50,000 |   |
|---------------------------|--------|---|--------|--------|

----

| 6.2.   | DOV                shall pay to Wyeth the Scheduled Payment set forth below within thirty                (30) days after achievement of the event corresponding to such Scheduled                Payment: |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **Event**                                                                                                                           |   | **Payment** |       |
|-------------------------------------------------------------------------------------------------------------------------------------|--------|-------------|------------|
| First                NDA (or equivalent) filing in the United States, Europe or Japan                for any                Product |   | $           | 2,500,000* |   |
| NDA                (or equivalent) approval in the United States, Europe or Japan for                any                Product     |   | $           | 4,500,000  |   |

*Wyeth      acknowledges and agrees that the $2,500,000 payment for the first NDA filing      set      forth above has been received by Wyeth and paid in full.*

*e.g.,*

| 6.3.   | Subject                to Section 6.4 below, DOV shall pay to Wyeth royalties in the amount                of                three and one-half percent (3.5%) of all Net Sales obtained by DOV                or its                Affiliates, in connection with the sale, or distribution or other                disposition of Product or Marketed Product in the Territory.                Notwithstanding the foregoing, if DOV sublicenses the Product or                Marketed                Product or otherwise enters into a Partnering Agreement with any                third                party relating to the development or commercialization of the Product                or                Marketed Product in one or more countries of the Territory, DOV shall                pay                to Wyeth royalties in the amount of four percent (4.0%) of all Net                Sales                obtained by DOV, its Affiliates, sublicensees or Commercial Partners                in                connection with the sale, distribution or other disposition of such                Product or Marketed Product in such country(ies) (it being understood                that                for all remaining countries royalties would remain payable at the                rates                set forth above). |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.4.   | Notwithstanding                any provision in this Agreement to the contrary, royalties shall                be                payable under Section 6.3 above with respect to the sale or distribution                or other disposition of Products or Marketed Products containing                as their                active ingredient(s) either of the compounds DOV21,947 or DOV102,677                (or                any prodrug, hydrate, solvate, salt form or polymoph thereof, but                not also                containing CL216,303 or any prodrug, hydrate, solvate, salt form                or                polymorph thereof), only in the event that (i) the composition or                use of                such compound, as applicable, is covered by a valid issued claim                (which                claim has not been declared unenforceable by a court of competent                jurisdiction and such decision is not appealable or has not been                appealed)                included within at least one of the Wyeth Patents in the country                of use or                sale as of such sale, distribution or other disposition or (ii) such                compound, as applicable, was discovered and developed by DOV without                the                non-deminimus use of any of the Wyeth Know-How which Wyeth Know-How                was                not in the public domain at the time of such use. It is understood                and                agreed that this Section 6.4 shall have no effect on DOV’s obligation to                pay royalties with respect to the sale or distribution or other                disposition of any Product or Marketed Product containing the compound                CL216,303 (or any prodrug, hydrate, solvate, salt form or polymoph                thereof). |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.5.   | DOV                shall keep and shall obligate its Affiliates, sublicensees and Commercial                Partners to keep accurate and complete records of all sales of Product                and                Marketed Product in accordance with generally accepted accounting                principles and practices. In any agreement between DOV and a third                party,                DOV shall obligate such third party to allow routine audits by Wyeth                of                such third party’s** **records                relating to the Product and Marketed Product and shall further require                such third party to likewise obligate any additional third party                that                enters into an agreement with the third party relating to the Product                and                Marketed Product to allow routine audits by Wyeth of such additional                third                party’s records relating to the Marketed Product. Wyeth, no more than one                time per calendar year for each of DOV or any third party so audited,                may                conduct, at its own expense, at reasonable times during normal business                hours, through an accountant designated by Wyeth and acceptable to                DOV                (and its sublicensees and their sublicensees, as appropriate), an                audit of                the accounts contemplated above, as well as any supporting instruments                and                documents, and may make copies of and extracts from such records                for the                sole purpose of ascertaining or verifying the correctness of the                amounts                remitted by DOV hereunder**.**Such                accountant shall be required by DOV or any sublicensee to enter into                a                reasonably acceptable confidentiality agreement, and in no event                shall                such accountants disclose to Wyeth or DOV any information other than                information relating to or supporting the accuracy of the payments                due                from DOV hereunder (and, except to the extent necessary to support                sales                data using bundles, in no event information that relates to products                other                than the Product and Marketed Product). Each such audit shall be                limited                to the records and accounts pertaining to the year on which the audit                is                conducted and the immediately preceding five (5) calendar years.                Results                in the form of a report of such audit shall be made available by                Wyeth to                DOV and to any third party that is the subject of the audit. Should                such                audit reveal any discrepancies between reports made by DOV or its                sublicensees and the audit exceeding five percent (5%) in favor of                DOV or                any third party that is audited, then DOV shall pay in full the costs                of                such audit requested by Wyeth; otherwise, Wyeth shall bear the costs                in                full for the audit of the records of DOV, its Affiliates, or its                sublicensees. In the event DOV, its Affiliates or sublicensees (including                further sublicensees) conducts an audit of any sublicensee selling                the                Marketed Product, DOV shall provide or shall cause such Affiliate                or                sublicensee to provide to Wyeth a copy of each audit report generated                in                connection therewith. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.6.   | Royalty                payments shall be due within sixty (60) days of the end of each calendar                quarter on Net Sales made in that quarter and shall be paid at Wyeth’s                Place of Payment. Royalties shall accrue in the currency of the country                in                which the sale of the Product or Marketed Product is made, and if                different from U. S. dollars shall be converted into such currency                using                the exchange rate appearing in the Wall                Street Journal                applicable for the last day of the calendar quarter during which                the                royalties accrued. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.7.   | All                taxes, assessments, fees, and charges, if any, levied under income                tax                laws or regulations with respect to payments due Wyeth hereunder                shall be                for the account of Wyeth and if required by law to be withheld and                paid to                the applicable jurisdiction, may be deducted by DOV from such payments                due                to Wyeth. Receipts for all such deducted taxes, assessments, fees                and                charges paid by DOV to the taxing authorities shall be secured by                DOV and                sent to Wyeth. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.8.   | In                case of any delay in payment by DOV to Wyeth not occasioned by force                majeure, interest at the rate of one percent (1%) per month, assessed                from                the thirty-first day after the due date of the said payment, shall                be due                Wyeth without any special notice. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      7.0**
**Confidentiality**

| 7.1.   | If                during the performance of this Agreement, one party hereto wishes                to                disclose information to another that it considers confidential, and                if the                receiving party is willing to accept such information, then such                information may not be subsequently disclosed by the receiving party                to a                third party, other than as provided in this Agreement, without the                written                permission of the disclosing party. The parties to this Agreement                shall                hold in confidence all information and all knowledge, know-how, practices,                process or other information disclosed or submitted in writing or                in other                tangible form that is considered to be confidential for a period                of five                (5) years from the date of such disclosure,                except: |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | information                that at the time of disclosure is in the public                domain; |
|-----------------|---------------------------------------------------------------------------------------------------|

| (b)   | information                that after disclosure is published or otherwise becomes part of the                public                domain through no fault of the receiving                party; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | information                that was in the possession of the receiving party at the time of                disclosure; |
|-----------------|------------------------------------------------------------------------------------------------------------------------|

----

| (d)   | information                that is developed by or on behalf of the receiving party independently                of                any disclosure to it by the disclosing party hereunder;                or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | information                that is provided to the receiving party by a third party with the                right to                so provide. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      8.0**
**Adverse      Experience**

| 8.1.   | DOV                shall keep (and DOV shall cause its sublicensees to keep under terms                and                conditions equal to those set forth in this Article                8.0)                Wyeth, during the term of this Agreement, promptly and fully informed                of                all pharmaceutical, toxicological and clinical findings relating                to                adverse experience of the Product or Marketed                Product. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.   | DOV                undertakes to notify Wyeth promptly with written confirmation by                immediate                telecopy of any information concerning any serious adverse event                as                defined by C.I.O.M.S. or the F.D.A. or by the Ministry of Health&                Welfare in Japan, as applicable, reasonably associated with clinical                studies or attributed to the use or application of the Product or                Marketed                Product. In any event the above notification shall be made within                two (2)                working days after DOV first learns or is advised of all relevant                information with respect to such serious adverse                event. |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3.   | DOV                shall also forward regularly (and usually every six months unless                the                parties agree on another period) to Wyeth any information on all                other                adverse effects or any difficulty associated with the clinical use,                studies, investigations, tests and prescription of the Product or                Marketed                Product. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4.   | DOV                shall provide upon request the information on estimated patient days                of                exposure. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.   | DOV                shall inform Wyeth, without delay, of any governmental action,                correspondence or reports to or from governmental authorities that                may                affect the situation of the Product or Marketed Product and furnish                Wyeth                with copies of any relevant documents relating                thereto. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      9.0**
**Representations      and Warranties**

| 9.1.   | Wyeth                hereby represents and warrants that it has the right to grant DOV                the                license under Article                2.0                of                this Agreement, and that, as of the Signature Date, Wyeth, to the                best of                its knowledge, is not a party to any lawsuit, opposition, re-examination                or interference contesting the validity of the Wyeth Patents.                Notwithstanding the foregoing, Wyeth makes no other warranties, expressed                or implied, and Wyeth does not warrant, nor does it entitle any agent,                officer, employee or representative of Wyeth to warrant, validity,                enforceability, efficacy, merchantability, fitness for a particular                purpose or otherwise with respect to Product, Marketed Product or                Wyeth                Patent as the case may be. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.   | DOV                is fully cognizant of Good Laboratory Practices (“GLP”)                and Good Manufacturing Practices (“GMP”)                and shall manufacture or have manufactured Product and Marketed Product                in                a manner that fully complies with GLP and                GMP. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      10.0**
**Indemnification,      Liability and Insurance**

| 10.1.   | DOV                shall at all times during the term of this Agreement, and thereafter,                indemnify, defend and hold Wyeth and all its Affiliates and their                respective directors, officers, partners, employees, servants and                agents                harmless from and against any and all claims and expenses, including                without limitation legal expenses, court costs, and reasonable attorney’s                fees, arising out of or relating to the death of or actual or alleged                injury to any person or damage to any third party’s property, and from and                against any other claim, proceeding, demand, expense, cost and liability                of any kind whatsoever (collectively “liabilities”)                resulting from, arising out of or related to Product or Marketed                Product. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.2.   | DOV                shall take all necessary steps, at its own costs, and shall so obligate                its sublicensee to properly maintain insurance policies to cover                all                liabilities to any third party that might be incurred, directly or                indirectly, as a result of its participation in the performance of                this                Agreement. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.   | DOV                shall maintain (and shall cause its sublicensee to maintain) product                liability insurance that may include funded self-insurance reserves                with                respect to the development, manufacture and sale of Product and Marketed                Product in such amount as customary in the industry. DOV (and its                sublicensee) shall maintain such insurance for so long as it continues                to                develop, manufacture or sell Product and Marketed Product and thereafter                for so long as required to cover such manufacture or                sales. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      11.0**
**Use      of Names/ Trademarks/Publicity**

| 11.1.   | Neither                party shall use the name or trademarks of the other party in any                advertising or other form of publicity without the written permission                of                the other party. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.   | By                virtue of this License Agreement, neither party shall acquire any                right to                use trademarks, tradedress or other indicia of origin belonging to                the                other party, or any of such other party’s                Affiliates. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3.   | The                timing and content of any press release or other public communications                relating to this Agreement and the transactions contemplated herein                shall,                except as otherwise required by law, be determined jointly by Wyeth                and                DOV. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      12.0**
**Patent      Maintenance, Infringements, and Interferences**

| 12.1.   | Wyeth                Patents. |
|-------------------|-------------------------------|

| (i)   | Prosecution                and Maintenance.                Wyeth shall be responsible for the preparation, filing, prosecution                and                maintenance (including, without limitation, any interferences,                oppositions, reissue proceedings and reexaminations), of the Wyeth                Patents. Wyeth shall reasonably consult with DOV with respect to                the                preparation, filing, prosecution and maintenance of the Wyeth Primary                Patents and DOV agrees to reasonably cooperate with Wyeth in such                activities. Wyeth shall keep DOV advised of the status of such activities                and shall also inform DOV in a timely manner of any material                communications Wyeth receives from the relevant patent office with                respect                to such activities. Wyeth shall give notice to DOV of any desire                to cease                preparation, filing, prosecution or maintenance of any Wyeth Primary                Patent on a country-by-country basis, and in such case, DOV shall                have the                right to elect to continue preparation, filing, prosecution and                maintenance of such Wyeth Primary Patent. In the event that DOV elects                to                continue any such activities for such Wyeth Primary Patent, DOV shall                reasonably consult with Wyeth with respect thereto and shall consider                in                good faith Wyeth’s reasonable views with respect to such activities, and                Wyeth agrees to transfer to DOV all information reasonably requested                by                DOV for DOV to conduct such activities and to otherwise reasonably                cooperate with DOV in such actions. DOV shall keep Wyeth advised                of the                status of such actions and shall also inform Wyeth in a timely manner                of                any material communications DOV receives from the relevant patent                office                with respect to such activities. Each party shall bear its own costs                with                respect to any preparation, filing, prosecution and maintenance of                any                Wyeth Patent for which it is responsible. Upon DOV’s reasonable request,                Wyeth shall consider in good faith prosecuting in a separate Patent                application any claim(s) concerning Product or Marketed Product that                if                separated into a separate Patent would thereby qualify as a “Wyeth Primary                Patent” under clause (iv) of that definition instead of being                included in another Wyeth Patent that is a “Wyeth Secondary Patent”                hereunder, provided that (i) such separation and additional Patent                shall not adversely affect the patentability, validity or enforceability                any of the other Wyeth Patents or any other Patents owned or controlled                by                Wyeth or any of its Affiliates, and (ii) DOV shall be responsible for                any incremental out-of-pocket costs incurred by Wyeth for preparing,                filing, prosecuting and maintaining such additional                Patent. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ii)   | Defense.                In the event that any actions, claims, demands, suits or other legal                proceedings are brought or threatened to be brought against DOV by                a third                party for infringement of such third party’s patent(s) relating to Product                per se (but not relating to formulation technology or general                manufacturing technology), by virtue of DOV’s manufacture, use, sale,                offer for sale, or importation of the Product or Marketed Product                hereunder, DOV shall notify Wyeth forthwith of the threat or existence                of                such actions with sufficient evidence thereof to enable the parties                to                prepare an appropriate defense strategy. The parties shall consult                together as to the action to be taken and as to how the defense will                be                handled. DOV shall be responsible for all defense                costs. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*provided      however,*

----

| (iii)   | Enforcement                - Wyeth Primary Patents.                Each party shall promptly inform the other party of any suspected                infringement of any of the Wyeth Primary Patents in the Field by                a third                party and provide the other party with any available evidence of                such                suspected infringement. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*provided,      however*

*provided,      however*

| (iv)   | Enforcement                - Wyeth Secondary Patents.                Each party shall promptly inform the other party of any suspected                infringement of any of the Wyeth Secondary Patents in the Field by                a third                party and provide the other party with any available evidence of                such                suspected infringement. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

*provided,      however*

----

| 12.2.   | DOV                Patents. |
|-------------------|-----------------------------|

| (i)   | Prosecution                and Maintenance.                DOV shall be responsible, at its own expense, for the preparation,                filing,                prosecution and maintenance (including, without limitation, any                interferences, oppositions, reissue proceedings and reexaminations)                of the                DOV Patents. Wyeth shall reasonably consult with DOV with respect                to the                preparation, filing, prosecution and maintenance of the DOV Patents.                DOV                shall keep Wyeth advised of the status of such activities and shall                also                inform Wyeth in a timely manner of any material communications DOV                receives from the relevant patent office with respect to such activities.                DOV shall give notice to Wyeth of any desire to cease preparation,                filing,                prosecution or maintenance of any DOV Patent on a country-by-country                basis, and in such case, to the extent not in conflict with DOV’s                obligations under any agreement under which DOV has licensed such                DOV                Patent to a third party for use in the Field (as of the Signature                Date or                thereafter), Wyeth shall have the right to elect to continue preparation,                filing, prosecution and maintenance of such DOV Patent. In the event                that                Wyeth elects to continue any such activities for such DOV Patent,                Wyeth                shall reasonably consult with DOV with respect thereto and shall                consider                in good faith Wyeth’s reasonable views with respect to such activities,                and DOV agrees to transfer to Wyeth all information reasonably requested                by Wyeth for Wyeth to conduct such activities and to otherwise reasonably                cooperate with Wyeth in such actions. Wyeth shall keep DOV advised                of the                status of such actions and shall also inform DOV in a timely manner                of any                material communications Wyeth receives from the relevant patent office                with respect to such activities. Each party shall bear its own costs                with                respect to any preparation, filing, prosecution and maintenance of                any DOV                Patent for which it is responsible. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ii)   | Enforcement.                Each party shall promptly inform the other party of any suspected                infringement of any of DOV Patents by a third party and provide the                other                party with any available evidence of such suspected infringement.                DOV                shall have the sole right, but not the obligation, to institute any                claim,                suit or proceeding against an infringer or a presumed infringer of                the DOV                Patents in the Field, and the first right, but not the obligation,                to                institute any claim, suit or proceeding against an infringer or a                presumed                infringer of the DOV Patents in the Retained Rights Field. DOV, at                its                sole expense, shall control the prosecution of any such suit or claim,                including without limitation the choice of counsel and shall settle                or                dispose of any such suit or claim, *provided,                however*,                that DOV shall have no right to diminish any of the rights granted                to                Wyeth hereunder in settling or disposing of any such claim. Wyeth                shall                provide DOV with all reasonable assistance (other than financial),                at                DOV’s expense, required to institute and maintain such                proceedings. |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*provided,      however*

----

**Article      13.0**
**Duration      and Termination**

| 13.1.   | This                Agreement shall be binding on the parties as of the day of its execution                but shall have no force or effect until either the parties determine                that                notification under Title II of the Hart-Scott-Rodino Antitrust                Improvements Act of 1976, 15 U.S.C. 18a, and the regulations promulgated                thereunder, 16 C.F.R. 801.1 et seq., is not required or if the parties                determine that such notification is required, the waiting period                shall                have expired or been terminated. If a notification filing is required,                the                parties shall, at their own expense, prepare and make all appropriate                filings. The parties shall cooperate in the antitrust clearance process                and hereby agree to furnish promptly to the FTC and the Antitrust                Division                of the Department of Justice such additional information reasonably                requested by them in connection with such filings. In the event that                the                waiting period has not expired or been terminated within six (6)                months after the date of signature of this agreement by both parties,                the                parties shall revert to their status before signing and this agreement                shall be of no force and effect, except for Articles 7, 10, and 11,                which                shall survive pursuant to their terms. Thereafter, the Agreement                shall                continue in full force and effect on a country by country basis until                the                later of (i) subject to Article 12.1(iii),                the last to expire of any valid and enforceable claims that are now                issued                or that issue at any time during the term of this Agreement under                the                Wyeth Patents in such country covering the use or sale of Marketed                Product                sold in such country, or (ii) a period of ten (10) years following                the launch of Marketed Product by DOV or any of its sublicensee(s)                in such                country. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.2.   | Upon                expiration of this Agreement with respect to a Marketed Product in                a                country of the Territory, the obligations of the parties under Article                3.4                with respect to such Marketed Product in such country shall no longer                apply and DOV shall be deemed to have a fully-paid, royalty-free,                non-exclusive license with the right to make or have made, use or                sell                Product and Marketed Product in such country as well as to freely                utilize                all data generated hereunder or received from Wyeth by DOV without                DOV’s                having further obligation to Wyeth, except for maintaining confidentiality                as required by Article 7.1                of                this Agreement and performing any obligations that survive expiration                of                this Agreement in accordance with Article 18.7. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.3.   | Subject                to Article 18.7,                DOV shall be free to terminate its rights and obligations under this                Agreement and surrender and return to Wyeth all rights acquired by                DOV                hereunder at any time upon ninety (90) days’ prior written notice to Wyeth                at which time all license rights granted by Wyeth to DOV hereunder                shall                come to an end. Upon Wyeth’s request after any such termination, DOV shall                assign to Wyeth all regulatory filings and approvals pertaining to                any                Product or Marketed Product and transfer to Wyeth all data and information                in DOV’s possession in connection therewith.                Such termination shall have no affect on the licenses granted by                DOV to                Wyeth under Article 2.4                (subject to Article 3.4). |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.4.   | In                the event that a party hereto breaches any material condition herein                contained, the other party may provide a formal written notice of                such                breach, requesting rectification within a sixty (60) day period from                the                date of receipt of such notice. The party alleged to be in breach                of this                Agreement shall either submit a commercially reasonable plan for                rectification within forty-five (45) days of receipt of notice (if                the                breach cannot be rectified within the sixty (60) day period), or                take                appropriate steps to remedy the breach if capable of remedy within                such                sixty (60) day period. If within the said sixty (60) day period neither                the aforesaid plan has been submitted, nor the breach cured, the                party                alleging breach shall then be entitled to terminate this Agreement,                thereby surrendering all rights granted to it hereunder, by written                notice                to the other party, such termination having immediate effect. Upon                Wyeth’s                request after any such termination by Wyeth, DOV shall assign to                Wyeth all                regulatory filings and approvals pertaining to any Product or Marketed                Product and transfer to Wyeth all data and information in DOV’s possession                in connection therewith.                Any termination under this Article 13.4                shall have no affect on the licenses granted to Wyeth under Article                2.4                (subject to Article 3.4). |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.5.   | This                Agreement may be terminated at once by Wyeth giving notice to DOV                if DOV                has committed an act of bankruptcy or an order is made or resolution                passed for the winding up of DOV. Upon Wyeth’s request after any such                termination by Wyeth, DOV shall assign to Wyeth all regulatory filings                and                approvals pertaining to any Product or Marketed Product and transfer                to                Wyeth all data and information in DOV’s possession in connection                therewith.                Any termination under this Article 13.5                shall have no affect on the licenses granted by DOV to Wyeth under                Article                2.4                (subject to Article 3.4). |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.6.   | In                the event this Agreement is terminated prior to its full term pursuant                to                Article 13.3                by                DOV or pursuant to Articles 13.4                or                13.5                by                Wyeth, DOV shall within thirty (30) days of such event transfer to                Wyeth                all information, data and know-how of any kind relating to each Product                and shall authorize the transfer of all governmental approvals for                the                Product to Wyeth, in addition to DOV’s right derived from all license                agreements between DOV and its third party partners relative to Product                and Marketed Product. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      14.0**
**Reports      and Notices**

| 14.1.   | Upon                Wyeth’s request, DOV shall provide Wyeth an annual report summarizing the                stage of development relating to the Product. Such report shall be                provided within thirty (30) days of each December 31 during the term                of                this Agreement. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.2.   | DOV                shall notify Wyeth in writing within fifteen (15) days after achieving                an                event that would require that a Scheduled Payment be paid by a third                party                to DOV, or by DOV to Wyeth, with respect to a                Product. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3.   | Not                later than sixty (60) days following the end of each quarter, DOV                will                provide Wyeth with a report summarizing the Net Sales of Marketed                Product                in each country in the Territory made by DOV or a third party sublicensee                of DOV. Such reporting shall begin following the first sale of Marketed                Product in the Territory. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.4.   | Any                notices or reports required or permitted to be given under this Agreement                shall be sent by certified or registered mail, or by an equivalent                service                that provides verification of delivery, return receipt requested                to the                respective party at the address stated below or such address as to                which                the parties are subsequently appropriately                notified: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| If                  to Wyeth: | Wyeth                  Pharmaceuticals                  |
|-------------------------------|---------------------------------------------------------|
|                          | 500                  Arcola Road                        |
|                          | Collegeville,                  PA 19426                 |
|                          | Attn:                  Senior Vice President, Licensing |

----

|                        | With                  a copy to:                                                                      |
|-----------------------------|-------------------------------------------------------------------------------------------------------|
|                        |                                                                                                  |
|                        | Wyeth                  Pharmaceuticals                                                                |
|                        | 500                  Arcola Road                                                                      |
|                        | Collegeville,                  PA 19426                                                               |
|                        | Attn:                  Vice President and Chief Counsel, Global Business                  Development |
|                        |                                                                                                  |
| If                  to DOV: | DOV                  Pharmaceutical, Inc.                                                             |
|                        | 150                  Pierce St.                                                                       |
|                        | Somerset,                  NJ 08873                                                                   |
|                        | Attn:                  President                                                                      |

**Article      15.0**
**Assignment**

| 15.1.   | This                Agreement shall be binding upon and inure to the benefit of the parties                hereto and the successors to substantially the entire business and                assets                of the respective parties hereto. Notwithstanding the foregoing,                either                party may void this Agreement if the Agreement is assigned for the                benefit                of a creditor. This Agreement shall not be assignable by either party                (except to an Affiliate, or in connection with the acquisition (whether                by                merger, consolidation, sale or otherwise) of a party or that part                of such                party’s business to which this Agreement relates), without the prior                written consent of the other party; any other attempted assignment                is                void. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      16.0**
**Applicable      Law**

| 16.1.   | This                Agreement shall be governed by and construed according to the laws                of the                State of New Jersey, USA. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      17.0**
**Force      Majeure**

| 17.1.   | None                of the parties shall be responsible for failure or delay in the                performance of any of its obligations hereunder due to Force Majeure.                Force Majeure shall mean any circumstance that, due to an event or                a legal                position beyond the party’s reasonable control, renders impossible the                fulfillment of any of the party’s obligations hereunder, such as, but not                limited to, acts of God, acts, regulations, or laws of any government,                war, civil commotion, destruction of facilities or materials by fires,                earthquakes, or storms, labor disturbances, shortages of public utilities,                common carriers, or raw materials, or any other cause, or causes                of                similar effects, except, however, any economic occurrence. During                any such                case of Force Majeure, this Agreement shall not be terminated, but                only                suspended and the party so affected shall continue to perform its                obligations as soon as such case of Force Majeure is removed or                alleviated. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      18.0**
**Miscellaneous**

| 18.1.   | This                Agreement and the Schedule and Exhibits hereto constitute the full                understanding and entire Agreement between the parties and supersede                and                replace any and all prior oral or written understandings and agreements                with respect to the subject matter hereof, including, without limitation,                the Prior Amended and Restated License Agreement. This Agreement                shall not                be effective until duly signed by officers of both Wyeth and DOV.                No                terms, conditions, understandings or Agreements purporting to modify,                amend or vary this Agreement shall be binding unless made in writing                and                signed by the parties hereto. It is mutually agreed that no party                has                relied upon any representations or statements of any third party                except as                stated herein. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 18.2.   | The                invalidity or unenforceability of an Article or any part of an Article                of                this Agreement in any jurisdiction shall not cause the invalidity                of the                whole Agreement as to such jurisdiction, and shall not affect the                validity                or enforceability of such Article or such part of an Article in any                other                jurisdiction. The parties shall replace any Article or part of an                Article                found invalid or unenforceable by alternative provisions that shall                be as                similar as possible in their conditions with regard to their spirit                and                commercial effect. If this Agreement in any jurisdiction is found                to be                invalid or unenforceable, the parties shall replace it by an alternative                agreement that shall be as similar as possible in its conditions                with                regard to its spirit and commercial                effect. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.3.   | The                failure of either party on any occasion to require the performance                by the                other of any provision hereof shall not affect the right of such                party to                enforce the same on a subsequent occasion. The waiver by either party                of                any breach of any provision hereof shall not be construed to be a                waiver                of any succeeding breach of that or any other provision or a waiver                of the                provision itself. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.4.   | This                Agreement shall not constitute either party as the joint venturer,                legal                representative or agent of the other party for any purpose whatsoever.                Neither party shall have any right or authority to assume or create                any                obligation or responsibility                for or on behalf of the other party or to otherwise bind the other                party. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.5.   | The                parties recognize that this is a master Agreement covering a number                of                countries. If for any country in the Territory it becomes necessary                to                execute a separate instrument for such country in order to satisfy                local                regulatory requirements, the parties shall execute such further instrument                that shall to the extent permitted by the laws of the country conform                to                the terms and conditions of this                Agreement. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.6.   | This                Agreement and the Schedule and Exhibits hereto are originally prepared                and                signed in the English language. If any translation into any other                language                is legally required for purposes of governmental filings, the parties                shall arrange for such translation, and the costs thereof shall be                borne                by the party legally required to make such filing. In the event of                any                question or dispute as to the meaning or interpretation of any term,                condition or provision of this Agreement, or any Schedule or Exhibit                hereto, the English language version shall in all events govern for                all                purposes whatsoever. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 18.7.   | Termination                of this Agreement for any reason, or expiration of this Agreement,                shall                not affect: (i) obligations, including the payment of any Scheduled                Payments or royalties that have accrued as of the date of termination                or                expiration and (ii) rights and obligations that, from the context                thereof,                are intended to survive termination or expiration of this Agreement,                including, without limitation, Articles 2.2,                2.4,                3.4,                8.2-8.4,                14.2                (with respect to activities occurring prior to such expiration or                termination), 14.3                (with respect to activities occurring prior to such expiration or                termination) and 14.4                and Articles 6 (with respect to any payments resulting from activities                arising prior to such expiration or termination), 7, 10, 11, 15,                16 and                18. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 18.8.   | This                Agreement is executed simultaneously in counterparts, each of which                shall                be deemed an original, but all of which shall constitute but one                and the                same instrument. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*remainder      of this page intentionally left blank*

----

| **WYETH                HOLDINGS CORPORATION**        |   |   | **DOV                PHARMACEUTICAL, INC.**                |
|------------------------------------------------------|--------|--------|------------------------------------------------------------|
|                                                 |   |   |                                                       |
|                                                 |   |   |                                                       |
| /s/                Ronald W. Alice                   |   |   | /s/                Scott Myers                             |
| NAME:                Ronald                W. Alice  |   |   | NAME:                Scott                Myers            |
| TITLE:                Vice                President  |   |   | TITLE:                Senior Vice                President |
| DATE:                December                7, 2006 |   |   | DATE:                December                7, 2006       |

| **WYETH,                acting through its****Wyeth                Pharmaceuticals Division** |   |   |   |
|-----------------------------------------------------------------------------------------------|--------|--------|--------|
|                                                                                          |   |   |   |
|                                                                                          |   |   |   |
| /s/                Ronald W. Alice                                                            |   |   |        |
| NAME:                Ronald                W. Alice                                           |   |   |        |
| TITLE:                Vice                President                                           |   |   |        |
| DATE:                December                7, 2006                                          |   |   |   |

----

**SCHEDULE      1**

**PRODUCTS**

----

**EXHIBIT      A**

**Wyeth      Patents**

----

**EXHIBIT      B**

**DOV      Patents**

----